Thermo Fisher Scientific Inc. (NYSE:TMO) Position Decreased by Kavar Capital Partners Group LLC

Kavar Capital Partners Group LLC lowered its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 28,880 shares of the medical research company’s stock after selling 35 shares during the period. Thermo Fisher Scientific comprises approximately 2.5% of Kavar Capital Partners Group LLC’s holdings, making the stock its 9th largest position. Kavar Capital Partners Group LLC’s holdings in Thermo Fisher Scientific were worth $15,024,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Pacer Advisors Inc. raised its holdings in Thermo Fisher Scientific by 9.1% during the fourth quarter. Pacer Advisors Inc. now owns 31,559 shares of the medical research company’s stock worth $16,418,000 after purchasing an additional 2,642 shares during the last quarter. United Asset Strategies Inc. increased its position in Thermo Fisher Scientific by 4.3% during the fourth quarter. United Asset Strategies Inc. now owns 27,269 shares of the medical research company’s stock worth $14,186,000 after buying an additional 1,118 shares in the last quarter. Cornerstone Wealth Group LLC raised its stake in Thermo Fisher Scientific by 4.2% in the 4th quarter. Cornerstone Wealth Group LLC now owns 1,089 shares of the medical research company’s stock valued at $567,000 after purchasing an additional 44 shares during the last quarter. Union Bancaire Privee UBP SA purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $71,877,000. Finally, Capital Asset Advisory Services LLC grew its position in shares of Thermo Fisher Scientific by 2.1% in the fourth quarter. Capital Asset Advisory Services LLC now owns 6,075 shares of the medical research company’s stock valued at $3,232,000 after purchasing an additional 127 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 5,850 shares of the company’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $557.89, for a total value of $3,263,656.50. Following the completion of the transaction, the chief executive officer now owns 121,192 shares in the company, valued at approximately $67,611,804.88. This represents a 4.60 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last quarter, insiders sold 34,850 shares of company stock valued at $19,123,197. 0.34% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO opened at $575.21 on Monday. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64. The firm’s 50-day moving average price is $533.60 and its two-hundred day moving average price is $569.81. The stock has a market capitalization of $220.02 billion, a P/E ratio of 36.06, a P/E/G ratio of 3.82 and a beta of 0.76. Thermo Fisher Scientific Inc. has a 52-week low of $493.30 and a 52-week high of $627.88.

Thermo Fisher Scientific declared that its board has initiated a stock repurchase plan on Friday, November 15th that authorizes the company to repurchase $4.00 billion in shares. This repurchase authorization authorizes the medical research company to repurchase up to 2% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th were given a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.27%. The ex-dividend date was Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio is presently 9.78%.

Analysts Set New Price Targets

A number of brokerages have weighed in on TMO. Stephens began coverage on shares of Thermo Fisher Scientific in a report on Tuesday, October 1st. They issued an “overweight” rating and a $680.00 price target on the stock. Wells Fargo & Company cut their price target on shares of Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating on the stock in a report on Thursday, October 24th. Barclays cut their target price on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 23rd. Scotiabank initiated coverage on Thermo Fisher Scientific in a report on Monday, December 23rd. They issued a “sector perform” rating and a $605.00 price target for the company. Finally, TD Cowen upped their target price on Thermo Fisher Scientific from $656.00 to $686.00 in a research report on Tuesday, October 22nd. Four research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $648.95.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.